These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 32143905)
41. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613 [TBL] [Abstract][Full Text] [Related]
42. Understanding tumor-infiltrating lymphocytes by single cell RNA sequencing. Ren X; Zhang Z Adv Immunol; 2019; 144():217-245. PubMed ID: 31699218 [TBL] [Abstract][Full Text] [Related]
43. Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. Germain C; Devi-Marulkar P; Knockaert S; Biton J; Kaplon H; Letaïef L; Goc J; Seguin-Givelet A; Gossot D; Girard N; Validire P; Lefèvre M; Damotte D; Alifano M; Lemoine FM; Steele KE; Teillaud JL; Hammond SA; Dieu-Nosjean MC Front Immunol; 2021; 12():626776. PubMed ID: 33763071 [TBL] [Abstract][Full Text] [Related]
44. Phenotypic analysis of T lymphocytes isolated from non-small-cell lung cancer. Riemann D; Wenzel K; Schulz T; Hofmann S; Neef H; Lautenschläger C; Langner J Int Arch Allergy Immunol; 1997 Sep; 114(1):38-45. PubMed ID: 9303329 [TBL] [Abstract][Full Text] [Related]
45. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas. Kayser G; Schulte-Uentrop L; Sienel W; Werner M; Fisch P; Passlick B; Zur Hausen A; Stremmel C Lung Cancer; 2012 Jun; 76(3):445-51. PubMed ID: 22300751 [TBL] [Abstract][Full Text] [Related]
46. Distribution of CD4(+) and CD8(+) T cells in tumor islets and stroma from patients with non-small cell lung cancer in association with COPD and smoking. Jackutė J; Žemaitis M; Pranys D; Šitkauskienė B; Miliauskas S; Bajoriūnas V; Sakalauskas R Medicina (Kaunas); 2015 Nov; 51(5):263-71. PubMed ID: 26674143 [TBL] [Abstract][Full Text] [Related]
47. Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence. Peng H; Wu X; Zhong R; Yu T; Cai X; Liu J; Wen Y; Ao Y; Chen J; Li Y; He M; Li C; Zheng H; Chen Y; Pan Z; He J; Liang W Front Immunol; 2021; 12():750046. PubMed ID: 34804034 [TBL] [Abstract][Full Text] [Related]
48. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704 [TBL] [Abstract][Full Text] [Related]
49. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467 [TBL] [Abstract][Full Text] [Related]
50. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor. Zou MX; Lv GH; Wang XB; Huang W; Li J; Jiang Y; She XL Neurosurgery; 2019 Jun; 84(6):E318-E333. PubMed ID: 30032257 [TBL] [Abstract][Full Text] [Related]
51. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826 [TBL] [Abstract][Full Text] [Related]
52. Tumor mutational load, CD8 Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958 [TBL] [Abstract][Full Text] [Related]
53. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519 [TBL] [Abstract][Full Text] [Related]
54. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Lopci E; Toschi L; Grizzi F; Rahal D; Olivari L; Castino GF; Marchetti S; Cortese N; Qehajaj D; Pistillo D; Alloisio M; Roncalli M; Allavena P; Santoro A; Marchesi F; Chiti A Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1954-61. PubMed ID: 27251642 [TBL] [Abstract][Full Text] [Related]
55. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153 [TBL] [Abstract][Full Text] [Related]
56. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration. Perea F; Bernal M; Sánchez-Palencia A; Carretero J; Torres C; Bayarri C; Gómez-Morales M; Garrido F; Ruiz-Cabello F Int J Cancer; 2017 Feb; 140(4):888-899. PubMed ID: 27785783 [TBL] [Abstract][Full Text] [Related]
57. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248 [TBL] [Abstract][Full Text] [Related]
58. Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer. Verma R; Hanby AM; Horgan K; Verghese ET; Volpato M; Carter CR; Hughes TA Breast Cancer Res Treat; 2020 Aug; 183(1):49-59. PubMed ID: 32577938 [TBL] [Abstract][Full Text] [Related]
59. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506 [TBL] [Abstract][Full Text] [Related]
60. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]